by | Nov 28, 2022 | Publications
Open Forum Infect Dis. 2022 Oct 31;9(11):ofac574. doi: 10.1093/ofid/ofac574. eCollection 2022 Nov. ABSTRACT BACKGROUND: Patients with multiple myeloma are at higher risk for infections due to disease pathogenesis and administered therapies. The purpose of this study...
by | Nov 28, 2022 | Publications
Front Oncol. 2022 Nov 10;12:1014904. doi: 10.3389/fonc.2022.1014904. eCollection 2022. ABSTRACT V-type immunoglobulin domain-containing suppressor of T cell activation (VISTA) is considered as an immunosuppressive factor and potential therapeutic target for anticancer...
by | Nov 28, 2022 | Publications
Front Oncol. 2022 Nov 9;12:1038329. doi: 10.3389/fonc.2022.1038329. eCollection 2022. ABSTRACT Resistance to immunomodulatory drugs (IMiDs®) is a major cause of treatment failure, disease relapse and ultimately poorer outcomes in multiple myeloma (MM). In order to...
by | Nov 28, 2022 | Publications
Bull Exp Biol Med. 2022 Nov 28. doi: 10.1007/s10517-022-05651-8. Online ahead of print. ABSTRACT We studied suppressor potential of myeloid-derived suppressor cells (MDSC) in multiple myeloma patients, including before and after mobilization of hematopoietic stem...
by | Nov 27, 2022 | Publications
BMC Res Notes. 2022 Nov 26;15(1):352. doi: 10.1186/s13104-022-06237-3. ABSTRACT OBJECTIVE: Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual...
by | Nov 26, 2022 | Publications
Hematol Oncol. 2022 Nov 26. doi: 10.1002/hon.3105. Online ahead of print. ABSTRACT The primary analysis of the phase 1/2 ISLANDs study in Japanese individuals with relapsed/refractory multiple myeloma (RRMM) showed that isatuximab monotherapy was well tolerated and...
